Results 1 to 10 of about 947,345 (358)

Targeting tumour microenvironment by tyrosine kinase inhibitor

Molecular Cancer, 2018
Tumour microenvironment (TME) is a key determinant of tumour growth and metastasis. TME could be very different for each type and location of tumour and TME may change constantly during tumour growth. Multiple counterparts in surrounding microenvironment
Hor-Yue Tan, Ning Wang, Wing Lam, Wei Guo, Yibin Feng, Yung-Chi Cheng   +5 more
doaj   +2 more sources

Combination Therapy With MET Tyrosine Kinase Inhibitor and EGFR Tyrosine Kinase Inhibitor in Patients With MET-Overexpressed EGFR-Mutant Lung Adenocarcinoma [PDF]

JTO Clinical and Research Reports
Introduction: Dysregulated MET signaling, such as MET overexpression or MET amplification (METamp), is a important mechanism of resistance to EGFR tyrosine kinase inhibitors (TKIs) in patients with EGFR-mutant lung adenocarcinoma (LUAD).
Jia-Jun Wu, MD, Zhe-Rong Zheng, MD, Tse-Hsien Lo, MD, Cheng-Hsiang Chu, MD, Kun-Chieh Chen, MD, PhD, Gee-Chen Chang, MD, PhD   +5 more
doaj   +2 more sources

Durable Response to Pazopanib (Tyrosine Kinase Inhibitor) in a Patient With EWSR1::CREM Gene Fusion Positive Intra-Abdominal Unclassified Epithelioid Sarcoma. [PDF]

Genes Chromosomes Cancer
Shafi S, Jones D, Pan X, Husain M, Rogers A, Oghumu S, Iwenofu OH.   +6 more
europepmc   +3 more sources

A Combination of L-Triiodothyronine and Levothyroxine in the Treatment of Tyrosine Kinase Inhibitor-Induced Hypothyroidism in Renal Cell Carcinoma: A Case Report. [PDF]

Clin Case Rep
Han YJ, Chen S, Miao R, Yu ZY, Wang YB.
europepmc   +3 more sources

Does thyroid dysfunction happen in CML patients receiving Imatinib for treatment? [PDF]

Reviews in Clinical Medicine, 2015
Chronic myelogenous leukemia is a myeloproliferative disorder presenting with anemia, elevated blood granulocytosis and the presence of immature granulocytes, basophilia, frequently thrombocytosis and spleen enlargement.
Hossein Rahimi, Zahra Mazloum Khorasani, Saeedeh Shariati   +2 more
doaj   +3 more sources

Protein tyrosine kinase inhibitor resistance in malignant tumors: molecular mechanisms and future perspective

Signal Transduction and Targeted Therapy, 2022
Protein tyrosine kinases (PTKs) are a class of proteins with tyrosine kinase activity that phosphorylate tyrosine residues of critical molecules in signaling pathways.
Yang Yang, Shuo Li, Yujiao Wang, Yi Zhao, Qiuhua Li   +4 more
semanticscholar   +1 more source

Second‐line therapy with first‐ or second‐generation tyrosine kinase inhibitors in EGFR‐mutated non‐small cell lung cancer patients with T790M‐negative or unidentified mutation

Thoracic Cancer, 2021
Background T790M mutation causes resistance to tyrosine kinase inhibitors (TKIs) in approximately 49% of patients with epidermal growth receptor‐mutant non‐small cell lung cancer (NSCLC).
Tadashi Nishimura, Tomohito Okano, Masahiro Naito, Soichi Iwanaka, Ayaka Ohiwa, Yasumasa Sakakura, Taro Yasuma, Hajime Fujimoto, Corina N. D'Alessandro‐Gabazza, Yasuhiro Oomoto, Tetsu Kobayashi, Esteban C. Gabazza, Hidenori Ibata   +12 more
doaj   +1 more source

Real world treatment sequences and outcomes for metastatic renal cell carcinoma.

PLoS ONE, 2023
ObjectivesThe treatment landscape for metastatic renal cell carcinoma changed a lot in the last few years. This study aimed to assess the treatment sequences and outcomes for metastatic renal cell carcinoma in a real-world setting.Materials and methodsWe
Gu-Shun Lai, Jian-Ri Li, Shian-Shiang Wang, Chuan-Shu Chen, Chun-Kuang Yang, Chia-Yen Lin, Sheng-Chun Hung, Kun-Yuan Chiu, Shun-Fa Yang   +8 more
doaj   +1 more source

Inhibitory effects of regorafenib, a multiple tyrosine kinase inhibitor, on corneal neovascularization [PDF]

International Journal of Ophthalmology, 2014
AIM:To evaluate the inhibitory effects of regorafenib (BAY 73-4506), a multikinase inhibitor, on corneal neovascularization (NV).METHODS:Thirty adult male Sprague-Dawley rats weighing 250-300 g, were used.
Halil Ibrahim Onder, Mesut Erdurmus, Yasin Yücel Bucak, Hüseyin Simavli, Murat Oktay, Ahmet Sahap Kukner   +5 more
doaj   +1 more source

Preclinical Activity of HER2-Selective Tyrosine Kinase Inhibitor Tucatinib as a Single Agent or in Combination with Trastuzumab or Docetaxel in Solid Tumor Models

Molecular Cancer Therapeutics, 2020
HER2 is a transmembrane tyrosine kinase receptor that mediates cell growth, differentiation, and survival. HER2 is overexpressed in approximately 20% of breast cancers and in subsets of gastric, colorectal, and esophageal cancers. Both antibody and small-
Anita Kulukian, Patrice A Lee, Janelle Taylor, R. Rosler, P. de Vries, Daniel Watson, A. Forero-Torres, S. Peterson   +7 more
semanticscholar   +1 more source